

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 09/630,319

ATTY. DOCKET NO.: C1039.70042US00

FILING DATE: July 31, 2000

CONFIRMATION NO.: 5464


APPLICANT: Krieg et al.

GROUP ART UNIT: 1648

EXAMINER: Emily M. Le

Sheet

19

**U.S. PATENT DOCUMENTS**

Examiner's Initials ^a	Cite U.S. Patent Document Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
	5,023,243		Tullis	06-11-1991
	5,457,189		Crooke et al.	10-10-1995
	5,498,410		Gleich	03-12-1996
	5,514,577		Draper et al.	05-07-1996
	5,567,604		Rando et al.	10-22-1996
	5,679,354		Morein et al.	10-24-1997
	5,681,555		Gleich	10-28-1997
	5,684,147		Agrawal et al.	11-04-1997
	6,027,732		Morein et al.	02-22-2000
	6,030,955		Stein et al.	02-29-2000
	6,184,369	B1	Rando et al.	02-06-2001
	6,210,663	B1	Ertl	04-03-2001
	6,426,334	B1	Agrawal et al.	07-30-2002
	6,498,147	B1	Nerenberg et al.	12-24-2002
	6,503,533	B1	Korba et al.	01-07-2003
	6,558,670	B1	Friede et al.	05-06-2003
	6,610,661	B1	Carson et al.	08-26-2003
	6,737,066	B1	Moss	05-18-2004
	6,821,957	B1	Krieg et al.	11-23-2004
	6,835,395	B1	Semple et al.	12-28-2004
	2003-0072762	A1	Van de Winkel et al.	04-17-2003
	2003-0125279	A1	Junghans et al.	07-03-2003
	2004-0009942	A1	Van Nest et al.	01-15-2004
	2004-0013688	A1	Wise et al.	01-22-2004
	2004-0038922	A1	Haensler et al.	02-26-2004
	2004-0092468	A1	Schwartz et al.	05-13-2004
	2004-0105872	A1	Klinman et al.	06-03-2004
	2004-0115219	A1	Ahn et al.	06-17-2004
	2004-0191833	A1	Fink et al.	09-30-2004
	2004-0229835	A1	Krieg et al.	11-18-2004
	2004-0234512	A1	Wagner et al.	11-25-2004
	2004-0235770	A1	Davis et al.	11-25-2004
	2004-0235774	A1	Bratzler et al.	11-25-2004

EXAMINER:

DATE CONSIDERED:

^a EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.:	09/630,319	ATTY. DOCKET NO.:	C1039.70042US00
FILING DATE:	July 31, 2000	CONFIRMATION NO.:	5464
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

Sheet 2 of 19

	2004-0235777	A1	Wagner et al.	11-25-2004
	2004-0235778	A1	Wagner et al.	11-25-2004
	2004-0247662	A1	Dow et al.	12-09-2004
	2004-0266719	A1	McCluskie et al.	12-30-2004
	2005-0004061	A1	Krieg et al.	01-06-2005
	2005-0004062	A1	Krieg et al.	01-06-2005
	2005-0009774	A1	Krieg et al.	01-13-2005
	2005-0013812	A1	Dow et al.	01-20-2005
	2005-0019340	A1	Garcon et al.	01-27-2005
	2005-0032734	A1	Davis et al.	02-10-2005
	2005-0032736	A1	Krieg et al.	02-10-2005
	2005-0037403	A1	Krieg et al.	02-17-2005
	2005-0037985	A1	Krieg et al.	02-17-2005
	2005-0042203	A1	Davis et al.	02-24-2005
	2005-0043529	A1	Davis et al.	02-24-2005
	2005-0049215	A1	Krieg et al.	03-03-2005
	2005-0049216	A1	Krieg et al.	03-03-2005
	2005-0054601	A1	Wagner et al.	03-10-2005
	2005-0054602	A1	Krieg et al.	03-10-2005
	2005-0059619	A1	Krieg et al.	03-17-2005
	2005-0059625	A1	Krieg et al.	03-17-2005
	2005-0059626	A1	Van Nest et al.	03-17-2005
	2005-0079152	A1	Bot et al.	04-14-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials *	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		EP	0 174 143	B1	Genentech, Inc.	11-08-1989	
		EP	0 286 224	B1	HEM Pharmaceuticals Corp.	11-25-1992	
		GB	2 216 416	A	Sandoz Ltd.	10-11-1989	
		KR	2001063153		Genexine Inc.	07-09-2001	Abstract
		WO	92/04381	A1	Scotgen Limited	03-19-1992	
		WO	94/01550	A1	Hybridon, Inc.	01-20-1994	
		WO	97/28259	A1	The Regents of the University of California	08-07-1997	
		WO	97/30731	A3	The Immune Response Corporation	08-28-1997	
		WO	98/49288	A1	Hybridon, Inc.	11-05-1998	

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.:	09/630,319	ATTY. DOCKET NO.:	C1039.70042US00
FILING DATE:	July 31, 2000	CONFIRMATION NO.:	5464
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

Sheet 3 of 19

	WO	99/33488	A2	SmithKline Beecham Biologicals S.A.	07-08-1999	
	WO	99/41368	A2	Maxygen, Inc.	08-19-1999	
	WO	99/52549	A1	SmithKline Beecham Biologicals S.A.	10-29-1999	
	WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999	
	WO	99/58118	A2	CPG Immunopharmaceuticals GMBH	11-18-1999	
	WO	99/61592	A1	Cheil-Jedang Corporation	12-02-1999	
	WO	00/15256	A2	Pasteur Mérieux Serums Et Vaccins [FR]	03-23-2000	Abstract
	WO	00/20039	A1	Regents of the University of California	04-13-2000	
	WO	00/41463	A2	SmithKline Beecham Biologicals, S.A.	07-20-2000	
	WO	00/54803	A2	Panacea Pharmaceuticals, LLC.	09-21-2000	
	WO	00/61151	A2	The Government of the United States of America	10-19-2000	
	WO	00/67787	A2	The Immune Response Corporation	11-16-2000	
	WO	01/22972	A2	Coley Pharmaceuticals, GmbH	04-05-2001	
	WO	01/22990	A2	Coley Pharmaceutical Group, Inc.	04-05-2001	
	WO	01/35991	A2	Dynavax Technologies Corporation	05-25-2001	
	WO	01/45750	A1	Regents of the University of California	06-28-2001	
	WO	01/55341	A2	The Regents of the University of California	08-02-2001	
	WO	01/55386	A1	Glaxo-Smithkline	08-02-2001	
	WO	01/76642	A1	Regents of the University of California	10-18-2001	
	WO	01/93902	A2	Biosynexus Incorporated	12-13-2001	
	WO	02/28428	A2	Aventis Pasteur [FR]	04-11-2002	Abstract
	WO	02/074921	A2	Cellular Genomics Inc.	09-26-2002	
	WO	03/002065	A2	Chiron Corporation	01-09-2003	
	WO	03/020889	A2	3M Innovative Properties Company	03-13-2003	
	WO	03/025119	A2	Medarex Inc.	03-27-2003	
	WO	03/030656	A2	Qiagen GMBH [DE]	04-17-2003	
	WO	03/043572	A2	3M Innovative Properties Company	05-30-2003	
	WO	03/047524	A2	Dana-Farber Cancer Institute	06-12-2003	
	WO	03/094963	A2	INEX Pharmaceuticals Corp.	11-20-2003	
	WO	03/100040	A1	Merck Patent GMBH	12-04-2003	
	WO	2004/007743	A2	Coley Pharmaceutical GMBH	01-22-2004	
	WO	2004/039829	A2	Coley Pharmaceutical Group, Ltd.	05-13-2004	

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1648	EXAMINER: Emily M. Le
Sheet	4	of	19		

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials ^a	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] DNA is the primary genetic material. <i>in</i> Recombinant DNA, Second Edition. Watson et al., editors. Scientific American Books, New York. p24-5, 147. Exhibit 1003.	
		[No Author Listed] Definitions. in The Dictionary of Immunology, Fourth Edition. Herbert et al., editors. Academic Press, 1995. p10. Exhibit 1004.	
		[No Author Listed] http://www.doctorfungus.com/the_fungi/Cryptococcus.htm . Exhibit 1029.	
		[No Author Listed] http://www.doctorfungus.com/the_fungi/Blastomyces.htm . Exhibit 1030.	
		[No Author Listed] http://www.doctorfungus.com/the_fungi/Alternaria.htm . Exhibit 1031.	
		[No Author Listed] http://www.cancer.gov/newscenter/pressreleases/cancervaccines . Exhibit 1042.	
		[No Author Listed] http://www.cancer.gov/clinicaltrials/learning/cancervaccines/print . Exhibit 1043.	
		[No Author Listed] Recombinant DNA Technology. in Molecular Biology of the Cell. Alberts et al., editors. Garland Publishing, Inc. 1983. Exhibit 2027.	
		[No Author Listed] Definitions. in Dorland's Illustrated Medical Dictionary, Twenty-sixth Edition. W.B. Saunders Company, 1981. Exhibit 2032.	
		[No Author Listed] Macromolecules in Prokaryotic and Eukaryotic Cells. in Molecular Cell Biology, Darnell et al, Editors. W.H. Freeman and Company, 1986. Exhibit 2033.	
		[No Author Listed] Definitions. in Immunology, Roitt et al., Editors. Gower Medical Publishing Company, 1985. Exhibit 2035.	
		[No Author Listed] Definitions. in Webster's New Collegiate Dictionary. The G&C Merriam Company, 1981. p287. Exhibit 2070.	
		[No Author Listed] http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Cancer_Vaccines_Active_Specific_Immunotherapies.asp . Exhibit 2072.	
		[No Author Listed] http://www.plwc.org/plwc/mainconstructor . Exhibit 2073.	
		[No Author Listed] http://www.icare.org/treatment/tcwvt4.htm . Exhibit 2074.	
		[No Author Listed] Chapter 13: Cytokines. in Immunology, Second Edition. Janis Kuby, editor. W.H. Freeman and Company, New York, 1994. p297-323.	
		[No Author Listed] Allergen Nomenclature, List of Allergens (as of March 12, 2004).	
		[No Author Listed] Expert panel report 2: Guidelines for the diagnosis and management of asthma – Clinical practice guidelines. National Institutes of Health Publication. 1997 Jul; No. 97-4051:iii-79.	
		ABED et al., Interferon-gamma regulation of B lymphocyte differentiation: activation of B cells is a prerequisite for IFN-gamma-mediated inhibition of B cell differentiation. Cell Immunol. 1994 Feb;153(2):356-66.	
		AGRAWAL et al., Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595-9.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

^a EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/630,319		ATTY. DOCKET NO.: C1039.70042US00	
				FILING DATE: July 31, 2000		CONFIRMATION NO.: 5464	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	5	of	19				

	AGRAWAL et al., Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 2002 Mar;8(3):114-21.	
	AGRAWAL et al., Chapter 19: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. p525-43.	
	ASKEW et al., CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol. 2000 Dec 15;165(12):6889-95.	
	AURICCHIO et al., Role of macrophage phospholipase D in natural and CpG-induced antimycobacterial activity. Cell Microbiol. 2003 Dec;5(12):913-20.	
	BAUER et al., Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol. 2001 Apr 15;166(8):5000-7.	
	BAUER et al., DNA activates human immune cells through a CpG sequence-dependent manner. Immunology. 1999 Aug;97(4):699-705.	
	BRAZALOT-MILLAN et al., CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8.	
	BROIDE et al., DNA-Based immunization for asthma. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):453-6.	
	BRUNNER et al., Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol. 2000 Dec 1;165(11):6278-86.	
	CAPRON et al., Immunologic aspects of schistosomiasis. Annu Rev Med. 1992;43:209-18. Review. Exhibit 2068.	
	CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 1997 Nov 17;186(10):1621-2.	
	CELLA et al., Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999 Aug;5(8):919-23.	
	CELLA et al., Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol. 2000 Oct;1(4):305-10. Abstract only.	
	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93.	
	CHEADLE et al., Endotoxin filtration and immune stimulation improve survival from gram-negative sepsis. Surgery. 1991 Oct;110(4):785-91; discussion 791-2. Abstract only.	
	CHEHIMI et al., Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol. 2002 May 1;168(9):4796-801.	
	CHELVARAJAN et al., CpG oligodeoxynucleotides overcome the unresponsiveness of neonatal B cells to stimulation with the thymus-independent stimuli anti-IgM and TNP-Ficolil. Eur J Immunol. 1999 Sep;29(9):2808-18.	
	CHEN et al., Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol. 1998 Jul;72(7):5757-61.	
	CHOI et al., The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine. 2002 Mar 15;20(13-14):1733-40.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1648	EXAMINER: Emily M. Le
Sheet	6	of	19		

		CONG et al., The mucosal adjuvant activity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J Immunol. 1997 Dec 1;159(11):5301-8. Abstract only.	
		COOPER et al., Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluorix influenza vaccine. Vaccine. 2004 Aug 13;22(23-24):3136-43.	
		COSSUM et al., Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther. 1993 Dec;267(3):1181-90.	
		COWSERT et al., In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother. 1993 Feb;37(2):171-7.	
		CROOKE et al., Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin. Toxicol Appl Pharmacol. 1996 Sep;140(1):85-93. Abstract only.	
		DALOD et al., Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med. 2002 Feb 18;195(4):517-28.	
		DALPKE et al., CpG DNA in the prevention and treatment of infections. BioDrugs. 2002;16(6):419-31. Abstract only.	
		DAVIS et al., CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol. 1998 Jan 15;160(2):870-6.	
		DAVIS et al., CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 2000 Mar 17;18(18):1920-4.	
		DAVIS, Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol. 2000;247:171-83.	
		DEML et al., Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins. Clin Chem Lab Med. 1999 Mar;37(3):199-204.	
		DONAGHY et al., Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood. 2001 Oct 15;98(8):2574-6.	
		DREWS et al., The experimental and clinical use of immune-modulating drugs in the prophylaxis and treatment of infections. Infection. 1985;13 Suppl 2:S241-50. Abstract only.	
		DUMAIS et al., Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis. 2002 Oct 15;186(8):1098-105. Epub 2002 Sep 30.	
		DUNN et al., The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-60. Review.	
		DURHAM et al., Immunotherapy and allergic inflammation. Clin Exp Allergy. 1991 Jan;21 Suppl 1:206-10.	
		FEARON et al., The instructive role of innate immunity in the acquired immune response. Science. 1996 Apr 5;272(5258):50-3. Abstract only.	
		FERBAS et al., CD4+ blood dendritic cells are potent producers of IFN-alpha in response to in vitro HIV-1 infection. J Immunol. 1994 May 1;152(9):4649-62. Abstract only.	
		FRANCOIS et al., Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. Clin Immunol Immunopathol. 1988 Sep;48(3):297-306.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/630,319		ATTY. DOCKET NO.: C1039.70042US00	
				FILING DATE: July 31, 2000		CONFIRMATION NO.: 5464	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	7	of	19				

		FRISSORA et al., IFN-gamma-mediated inhibition of antigen receptor-induced B cell proliferation and CREB-1 binding activity requires STAT-1 transcription factor. <i>Eur J Immunol.</i> 2003 Apr;33(4):907-12.	
		FUJISAWA et al., Serial changes in titers of antibody to hepatitis B surface antigen after immunization of infants born to mothers with hepatitis B e antigen. <i>J Pediatr Gastroenterol Nutr.</i> 1996 Oct;23(3):270-4. Abstract only.	
		FULTZ et al., Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. <i>AIDS Res Hum Retroviruses.</i> 1992 Feb;8(2):313-7. Abstract only.	
		GALLICHAN et al., Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. <i>Vaccine.</i> 1995 Nov;13(16):1589-95.	
		GALLICHAN et al., Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. <i>J Immunol.</i> 2001 Mar 1;166(5):3451-7.	
		GAO et al., Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. <i>J Immunol.</i> 2001 Jun 1;166(11):6855-60.	
		GASTON et al., CpG methylation has differential effects on the binding of YY1 and ETS proteins to the bi-directional promoter of the Surf-1 and Surf-2 genes. <i>Nucleic Acids Res.</i> 1995 Mar 25;23(6):901-9.	
		GOMIS et al., Protection of chickens against <i>Escherichia coli</i> infections by DNA containing CpG motifs. <i>Infect Immun.</i> 2003 Feb;71(2):857-63.	
		GURSEL et al., Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. <i>J Immunol.</i> 2001 Sep 15;167(6):3324-8.	
		GOUTTEFANGEAS et al., Problem solving for tumor immunotherapy. <i>Nat Biotechnol.</i> 2000 May;18(5):491-2.	
		GRAMZINSKI et al., Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. <i>Infect Immun.</i> 2001 Mar;69(3):1643-9.	
		GRAMZINSKI et al., Immune response to a hepatitis B DNA vaccine in <i>Aotus</i> monkeys: a comparison of vaccine formulation, route, and method of administration. <i>Mol Med.</i> 1998 Feb;4(2):109-18. Abstract only.	
		GREGORIADIS et al., Liposomes for drugs and vaccines. <i>Trends Biotechnol.</i> 1985;3:235. Abstract only.	
		GURSEL et al., Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. <i>J Leukoc Biol.</i> 2002 May;71(5):813-20. Abstract only.	
		HALPERIN et al., A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. <i>Vaccine.</i> 2003 Jun 2;21(19-20):2461-7. Abstract only.	
		HARTMANN et al., CpG DNA and LPS induce distinct patterns of activation in human monocytes. <i>Gene Ther.</i> 1999 May;6(5):893-903.	
		HARTMANN et al., Mechanism and function of a newly identified CpG DNA motif in human primary B cells. <i>J Immunol.</i> 2000 Jan 15;164(2):944-53.	
		HARTMANN et al., Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. <i>J Immunol.</i> 2000 Feb 1;164(3):1617-24.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.:	09/630,319	ATTY. DOCKET NO.:	C1039.70042US00
FILING DATE:	July 31, 2000	CONFIRMATION NO.:	5464
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

Sheet 8 of 19

	HARTMANN et al., CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. <i>Proc Natl Acad Sci U S A</i> . 1999 Aug 3;96(16):9305-10.	
	HASLETT et al., Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. <i>J Infect Dis</i> . 2000 Apr;181(4):1264-72. Epub 2000 Apr 05.	
	HAVLIR et al., Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. <i>AIDS Clinical Trials Group Study 343 Team. N Engl J Med</i> . 1998 Oct 29;339(18):1261-8.	
	HEEG et al., CpG DNA as a Th1 trigger. <i>Int Arch Allergy Immunol</i> . 2000 Feb;121(2):87-97.	
	HINKULA et al., Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. <i>J Virol</i> . 1997 Jul;71(7):5528-39.	
	HO, Toward HIV eradication or remission: the tasks ahead. <i>Science</i> . 1998 Jun 19;280(5371):1866-7.	
	HOPKIN et al., BioMedNet, Issue 57, 6/25/1999.	
	HORNER et al., Mucosal adjuvanticity of immunostimulatory DNA sequences. <i>Springer Semin Immunopathol</i> . 2000;22(1-2):133-46.	
	HUANG et al., Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria. <i>Infect Immun</i> . 1999 Dec;67(12):6257-63.	
	HUNG et al., Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. <i>J Immunol</i> . 2001 May 1;166(9):5733-40.	
	HUNTER et al., Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. <i>Am J Obstet Gynecol</i> . 2001 Nov;185(5):1174-9.	
	IHO et al., Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro. <i>J Immunol</i> . 1999 Oct 1;163(7):3642-52.	
	IMAMI et al., Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. <i>AIDS Res Hum Retroviruses</i> . 1999 Nov 20;15(17):1499-508.	
	IOANNOU et al., The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. <i>J Virol</i> . 2002 Sep;76(18):9002-10.	
	JACKSON et al., Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. <i>RNA</i> . 1995 Dec;1(10):985-1000.	
	JAKOB et al., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. <i>J Immunol</i> . 1998 Sep 15;161(6):3042-9.	
	JAKOB et al., Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. <i>Int Arch Allergy Immunol</i> . 1999 Feb-Apr;118(2-4):457-61.	
	JARROSSAY et al., Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. <i>Eur J Immunol</i> . 2001 Nov;31(11):3388-93. Abstract only.	
	JIANG et al., Enhancing immunogenicity by CpG DNA. <i>Curr Opin Mol Ther</i> . 2003 Apr;5(2):180-5. Abstract only.	

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1648	EXAMINER: Emily M. Le
Sheet	9	of	19		

	JILEK et al., Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. <i>J Immunol.</i> 2001 Mar 1;166(5):3612-21. Exhibit 2036.	
	JOHNSON et al., Non-specific resistance against microbial infections induced by polyribonucleotide complexes. In: <i>Immunopharmacology of infection diseases: Vaccine adjuvants and modulators of non-specific resistance.</i> 1987: 291-301.	
	JURK et al., Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. <i>Nat Immunol.</i> 2002 Jun;3(6):499.	
	KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from <i>Mycobacterium bovis</i> BCG complexed with poly-L-lysine and carboxymethylcellulose. <i>Jpn J Med Sci Biol.</i> 1990 Oct;43(5):171-82.	
	KIEFT et al., The hepatitis C virus internal ribosome entry site adopts an ion-dependent tertiary fold. <i>J Mol Biol.</i> 1999 Sep 24;292(3):513-29. Abstract only.	
	KLINCK et al., A potential RNA drug target in the hepatitis C virus internal ribosomal entry site. <i>RNA.</i> 2000 Oct;6(10):1423-31.	
	KLINMAN et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. <i>J Immunol.</i> 1997 Apr 15;158(8):3635-9.	
	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. <i>Drug News Perspect.</i> 2000 Jun;13(5):289-96.	
	KLINMAN et al., Immunotherapeutic uses of CpG oligodeoxynucleotides. <i>Nat Rev Immunol.</i> 2004 Apr;4(4):249-58.	
	KLINMAN et al., CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. <i>Vaccine.</i> 2004 Jul 29;22(21-22):2881-6.	
	KOVARIK et al., CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. <i>J Immunol.</i> 1999 Feb 1;162(3):1611-7.	
	KRANZER et al., CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. <i>Immunology.</i> 2000 Feb;99(2):170-8.	
	KRIEG et al., American College of Rheumatology 58th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. <i>Arthritis Rheum.</i> 1994 Sep;37(9 Suppl).	
	KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal <i>L. monocytogenes</i> challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996:116.	
	KRIEG et al., Immune effects and therapeutic applications of CpG motifs in bacterial DNA. <i>Immunopharmacology.</i> 2000 Jul 25;48(3):303-5.	
	KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. <i>Immunol Today.</i> 2000 Oct;21(10):521-6.	
	KRIEG et al., Chapter 8: Immune Stimulation by Oligonucleotides. in <i>Antisense Research and Application.</i> Crooke, editor. 1998: 243-62.	
	KRIEG et al., Enhancing vaccines with immune stimulatory CpG DNA. <i>Curr Opin Mol Ther.</i> 2001 Feb;3(1):15-24.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1648	EXAMINER: Emily M. Le
Sheet	10	of	19		

	KRIEG et al., Ernst Schering Research Found Workshop, (30): 105-18, 2001.	
	KRIEG, Immune effects and mechanisms of action of CpG motifs. Vaccine. 2000 Nov 8;19(6):618-22.	
	KRIEG et al., Chapter 17: Immune stimulation by oligonucleotides. in Antisense Drug Tech. 2001;1394:471-515.	
	KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16.	
	KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.	
	KRIEG, The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb;12(1):35-43.	
	KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.	
	KRIEG et al., Mechanisms and therapeutic applications of immune stimulatory CpG DNA. Pharmacol Ther. 1999 Nov;84(2):113-20.	
	KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.	
	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):97-105.	
	KRIEG, Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
	KRINGEL et al., CpG-oligodeoxynucleotides enhance porcine immunity to Toxoplasma gondii. Vet Parasitol. 2004 Aug 13;123(1-2):55-66.	
	KRUG et al., Identification of CpG oligonucleotide sequences with high induction of IFN- α /beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul;31(7):2154-63.	
	KRUG et al., Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct;31(10):3026-37.	
	KUCHAN et al., Nucleotides in infant nutrition: effects on immune function. Pediatr Adolesc Med. 1998;8:80-94.	
	KUHOBER et al., DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J Immunol. 1996 May 15;156(10):3687-95. Abstract only.	
	KULKARNI et al., Effect of dietary nucleotides on response to bacterial infections. JPEN J Parenter Enteral Nutr. 1986 Mar-Apr;10(2):169-71. Abstract only.	
	KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992 Jul;14(5):773-82.	
	KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. Microbiol Immunol. 1989;33(11):929-40.	
	LEDERMAN et al., Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation. Antisense Nucleic Acid Drug Dev. 1996 Winter;6(4):281-9.	
	LEE et al., CpG motif in synthetic ODN primes respiratory burst of olive flounder Paralichthys olivaceus phagocytes and enhances protection against Edwardsiella tarda. Dis Aquat Organ. 2003 Aug 15;56(1):43-8.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/630,319		ATTY. DOCKET NO.: CI039.70042US00	
				FILING DATE: July 31, 2000		CONFIRMATION NO.: 5464	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	11	of	19				

		LEIBSON et al., Role of gamma-interferon in antibody-producing responses. <i>Nature</i> . 1984 Jun 28-Jul 4;309(5971):799-801.	
		LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. <i>Eur J Immunol</i> . 1997 Sep;27(9):2340-4.	
		LIPFORD et al., Bacterial DNA as immune cell activator. <i>Trends Microbiol</i> . 1998 Dec;6(12):496-500.	
		LIU et al., Recombinant interleukin-6 protects mice against experimental bacterial infection. <i>Infect Immun</i> . 1992 Oct;60(10):4402-6.	
		LOTZ et al., Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus. <i>J Rheumatol</i> . 1987 Feb;14(1):42-5.	
		LUTYNSKI et al., [The level of anti-HBs in blood serum of persons selected from a group of Krakow inhabitants] <i>Folia Med Cracov</i> . 1997;38(3-4):63-8. Polish. Abstract only.	Yes - Abstract
		MA et al., DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. <i>Vaccine</i> . 2002 Sep 10;20(27-28):3263-71.	
		MAGNUSSON et al., Importance of CpG dinucleotides in activation of natural IFN-alpha-producing cells by a lupus-related oligodeoxynucleotide. <i>Scand J Immunol</i> . 2001 Dec;54(6):543-50.	
		MALANCHERE-BRES et al., CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. <i>J Virol</i> . 2001 Jul;75(14):6482-91.	
		MANCILLA-RAMIREZ et al., [Phosphatidylcholine induces an increase in the production of interleukin-6 and improves survival of rats with neonatal sepsis caused by <i>Klebsiella pneumoniae</i>] <i>Gac Med Mex</i> . 1995 Jan-Feb;131(1):14-22. Spanish. Abstract only.	Yes - Abstract
		MARDH et al., <i>Alternaria alternata</i> as a cause of opportunistic fungal infections in man. <i>Scand J Infect Dis Suppl</i> . 1978;(16):36-40.	
		MARTIN-OROZCO et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. <i>Int Immunol</i> . 1999 Jul;11(7):1111-8.	
		MARTINEZ-MAZA et al., Interleukin 6 and cancer treatment. <i>In Vivo</i> . 1991 Nov-Dec;5(6):583-8. Abstract only.	
		MATSUKURA et al., Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. <i>Proc Natl Acad Sci U S A</i> . 1989 Jun;86(11):4244-8.	
		MCCLUSKIE et al., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. <i>J Immunol</i> . 1998 Nov 1;161(9):4463-6.	
		MCCLUSKIE et al., CpG DNA as mucosal adjuvant. <i>Vaccine</i> . 18: 231-237, 2000.	
		MCCLUSKIE et al., Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. <i>Vaccine</i> . 2000 Oct 15;19(4-5):413-22.	
		MCCLUSKIE et al., Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. <i>Viral Immunol</i> . 1998;11(4):245-52.	
		MCCLUSKIE et al., CpG DNA is an effective oral adjuvant to protein antigens in mice. <i>Vaccine</i> . 2000 Nov 22;19(7-8):950-7.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/630,319		ATTY. DOCKET NO.: C1039.70042US00	
				FILING DATE: July 31, 2000		CONFIRMATION NO.: 5464	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	12	of	19				

		MCCLUSKIE et al., The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine. 2001 Mar 21;19(17-19):2657-60.	
		MCCLUSKIE et al., The use of CpG DNA as a mucosal vaccine adjuvant. Curr Opin Investig Drugs. 2001 Jan;2(1):35-9.	
		MCCLUSKIE et al., Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):179-85.	
		MCCLUSKIE et al., The role of CpG in DNA vaccines. Springer Semin Immunopathol. 2000;22(1-2):125-32.	
		MCCLUSKIE et al., Novel adjuvant systems. Curr Drug Targets Infect Disord. 2001 Nov;1(3):263-71.	
		METZGER et al., Enhancement of humoral immunity by interleukin-12. Ann N Y Acad Sci. 1996 Oct 31;795:100-15.	
		MOISAN et al., Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nrampl (resistance allele). Antimicrob Agents Chemother. 2001 Nov;45(11):3059-64.	
		MONDOVEANU et al., CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 1998 Jul;16(11-12):1216-24.	
		MOND et al., Recombinant interferon-gamma inhibits the B cell proliferative response stimulated by soluble but not by Sepharose-bound anti-immunoglobulin antibody. J Immunol. 1985 Oct;135(4):2513-7.	
		MOSS et al., In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides. Vaccine. 2000 Jan 6;18(11-12):1081-7.	
		MUDD et al., The effect of nonspecific immune stimulation on the recurrence rate of herpetic keratitis in rabbits. Invest Ophthalmol. 1975 Jun;14(6):469-71. Abstract only.	
		O'HAGAN et al., Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng. 2001 Oct 15;18(3):69-85. Abstract only.	
		O'HAGAN et al., Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord. 2001 Nov;1(3):273-86. Abstract only.	
		ONYEBUJOH et al., Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir Med. 1995 Mar;89(3):199-207. Abstract only.	
		PAL et al., Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun. 2002 Sep;70(9):4812-7.	
		PASHENKOV et al., Recruitment of dendritic cells to the cerebrospinal fluid in bacterial neuroinfections. J Neuroimmunol. 2002 Jan;122(1-2):106-16. Abstract only.	
		PAYETTE et al., History of vaccines and positioning of current trends. Curr Drug Targets Infect Disord. 2001 Nov;1(3):241-7.	
		PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. Immunol Res. 1999;19(1):35-46.	
		PISETSKY et al., The influence of base sequence on the immunological properties of defined oligonucleotides. Immunopharmacology. 1998 Nov;40(3):199-208.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.:	09/630,319	ATTY. DOCKET NO.:	CI039.70042US00
FILING DATE:	July 31, 2000	CONFIRMATION NO.:	5464
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

Sheet 13 of 19

	PISETSKY et al., Immunological properties of bacterial DNA. Ann N Y Acad Sci. 1995 Nov 27;772:152-63.	
	RAGHAVAN et al., Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection. Infect Immun. 2003 Dec;71(12):7014-22.	
	RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40.	
	RAY et al., Experimental Biology 2001. Orlando, Florida, USA. March 31-April 4, 2001. Abstracts, part II. FASEB J. 2001 Mar 8;15(5):A1007.	
	RAZ et al., Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9519-23.	
	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract Number 615.	
	REVAZ et al., The importance of mucosal immunity in defense against epithelial cancers. Curr Opin Immunol. 2005 Apr;17(2):175-9.	
	REYNOLDS et al., Inhibition of B lymphocyte activation by interferon-gamma. J Immunol. 1987 Aug 1;139(3):767-73.	
	ROTHENFUSSER et al., Recent advances in immunostimulatory CpG oligonucleotides. Curr Opin Mol Ther. 2003 Apr;5(2):98-106.	
	SAJIC et al., Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J Med Virol. 2003 Dec;71(4):561-8.	
	SANTELIZ et al., Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol. 2002 Mar;109(3):455-62. Exhibit 1041.	
	SATOH et al., Morphological and immunohistochemical characteristics of the heterogeneous prostate-like glands (paraurethral gland) seen in female Brown-Norway rats. Toxicol Pathol. 2001 Mar-Apr;29(2):237-41. Abstract only.	
	SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol. 1999 Jul 1;163(1):224-31.	
	SESTER et al., Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol. 2000 Oct 15;165(8):4165-73.	
	SIDMAN et al., Gamma-interferon is one of several direct B cell-maturing lymphokines. Nature. 1984 Jun 28-Jul 4;309(5971):801-4.	
	SINGH et al., Recent advances in veterinary vaccine adjuvants. Int J Parasitol. 2003 May;33(5-6):469-78. Abstract only.	
	SINGH et al., Recent advances in vaccine adjuvants. Pharm Res. 2002 Jun;19(6):715-28. Abstract only.	
	SJOLANDER et al., Iscoms containing purified Quilaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol. 1997 Apr 10;177(1):69-76.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1648	EXAMINER: Emily M. Le
Sheet	14	of	19		

		SOILLEUX et al., Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. <i>J Leukoc Biol.</i> 2002 Mar;71(3):445-57. Abstract only.	
		SPARWASSER et al., Bacterial DNA causes septic shock. <i>Nature.</i> 1997 Mar 27;386(6623):336-7.	
		SPARWASSER et al., Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. <i>Eur J Immunol.</i> 1998 Jun;28(6):2045-54.	
		SPENCER et al., Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin. <i>J Infect Dis.</i> 1977 Aug;136(2):171-5. Abstract only.	
		STEIN et al., Antisense oligonucleotides as therapeutic agents--is the bullet really magical? <i>Science.</i> 1993 Aug 20;261(5124):1004-12. Review.	
		SUN et al., Type I interferon-mediated stimulation of T cells by CpG DNA. <i>J Exp Med.</i> 1998 Dec 21;188(12):2335-42.	
		SUN et al., Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons. <i>Springer Semin Immunopathol.</i> 2000;22(1-2):77-84.	
		SUR et al., Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. <i>J Immunol.</i> 1999 May 15;162(10):6284-93.	
		THREADGILL et al., Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide. <i>Vaccine.</i> 1998 Jan;16(1):76-82.	
		TOKUNGA, Response of the organism to DNA - With a focus on immunostimulatory DNA. Kansen Ensho Meneki. 2001 Autumn; 31(3): 1-12. Japanese. Exhibits 1048 and 1049.	Yes
		TORTORA et al., Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. <i>Clin Cancer Res.</i> 2000 Jun;6(6):2506-12.	
		UHLMANN, Recent advances in the medicinal chemistry of antisense oligonucleotides. <i>Curr Opin Drug Discov Devel</i> 2000 Mar 29; 3(2):203-13.	
		UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. <i>Curr Opin Drug Discov Devel.</i> 2003 Mar;6(2):204-17.	
		VANDERLUGT et al., Epitope spreading in immune-mediated diseases: implications for immunotherapy. <i>Nat Rev Immunol.</i> 2002 Feb;2(2):85-95.	
		VERTHELYI et al., Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. <i>Clin Immunol.</i> 2003 Oct;109(1):64-71.	
		VERTHELYI et al., CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. <i>AIDS.</i> 2004 Apr 30;18(7):1003-8. Abstract only.	
		VERTHELYI et al., Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. <i>J Immunol.</i> 2001 Feb 15;166(4):2372-7.	
		VLASSOV et al., Oligonucleotides in cells and in organisms: pharmacological considerations. Prospects for Antisense Nucleic Acid Therapy of Cancer and Aids. 1991:243-66.	
		VOLLMER et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. <i>Eur J Immunol.</i> 2004 Jan;34(1):251-62.	
		VOLLMER et al., Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. <i>Antisense Nucleic Acid Drug Dev.</i> 2002 Jun;12(3):165-75.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.:	09/630,319	ATTY. DOCKET NO.:	C1039.70042US00
FILING DATE:	July 31, 2000	CONFIRMATION NO.:	5464
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

Sheet	15	of	19
-------	----	----	----

		VOLLMER et al., Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). <i>Oligonucleotides</i> . 2004 Spring;14(1):23-31.	
		VOLLMER et al., Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. <i>Antimicrob Agents Chemother</i> . 2004 Jun;48(6):2314-7.	
		WAAG et al., Injection of inactivated phase I <i>Coxiella burnetii</i> increases non-specific resistance to infection and stimulates lymphokine production in mice. <i>Ann N Y Acad Sci</i> . 1990;590:203-14.	
		WAGNER et al., Bacterial CpG DNA activates immune cells to signal infectious danger. <i>Adv Immunol</i> . 1999;73:329-68.	
		WAGNER, Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. <i>Curr Opin Microbiol</i> . 2002 Feb;5(1):62-9.	
		WALLNER et al., Immunotherapy with T-cell-reactive peptides derived from allergens. <i>Allergy</i> . 1994 May;49(5):302-8. Review.	
		WARREN et al., APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. <i>J Immunol</i> . 2000 Dec 1;165(11):6244-51.	
		WEERATNA et al., Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. <i>Antisense Nucleic Acid Drug Dev</i> . 1998 Aug;8(4):351-6.	
		WEERATNA et al., CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. <i>Immunol Cell Biol</i> . 2003 Feb;81(1):59-62.	
		WEERATNA et al., CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. <i>FEMS Immunol Med Microbiol</i> . 2001 Dec;32(1):65-71.	
		WEERATNA et al., CpG DNA induces stronger immune responses with less toxicity than other adjuvants. <i>Vaccine</i> . 2000 Mar 6;18(17):1755-62.	
		WEERATNA et al., Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. <i>FEMS Immunol Med Microbiol</i> . 2001 Apr;30(3):241-7.	
		WEERATNA et al., Optimization strategies for DNA vaccines. <i>Intervirology</i> . 2000;43(4-6):218-26.	
		WEIGHARDT et al., Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. <i>J Immunol</i> . 2000 Oct 15;165(8):4537-43.	
		WEINER et al., The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. <i>J Leukoc Biol</i> . 2000 Oct;68(4):455-63.	
		WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. <i>Proc Natl Acad Sci U S A</i> . 1997 Sep 30;94(20):10833-7.	
		WERNETTE et al., CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. <i>Vet Immunol Immunopathol</i> . 2002 Jan 15;84(3-4):223-36.	
		WHALEN et al., DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. <i>Ann N Y Acad Sci</i> . 1995 Nov 27;772:64-76. Review. Exhibit 2039.	
		WYATT et al., Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. <i>Proc Natl Acad Sci U S A</i> . 1994 Feb 15;91(4):1356-60.	

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1648	EXAMINER: Emily M. Le
Sheet	16	of	19		

		YAMAMOTO, Cytokine production inducing action of oligo DNA. Rinsho Meneki. 1997; 29(9): 1178-84. Japanese. Exhibits 1050, 1047, and 1046.	Yes
		YI et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. Journal of Immunology, 156(2): 558-64, 1996.	
		YI et al., CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol. 1996 Dec 1;157(11):4918-25.	
		YI et al. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol. 1998 Nov 1;161(9):4493-7.	
		YI et al. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol. 1998 Jun 15;160(12):5898-906.	
		ZHANG et al., Antigen- and isotype-specific immune responses to a recombinant antigen-allergen chimeric (RAAC) protein. J Immunol. 1993 Jul 15;151(2):791-9.	
		ZHAO et al., Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg Med Chem Lett. 2000 May 15;10(10):1051-4. Abstract Only.	
		ZHAO et al., Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg Med Chem Lett. 1999 Dec 20;9(24):3453-8. Abstract only.	
		ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-502.	
		ZHAO et al., Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg Med Chem Lett. 1999 Dec 20;9(24):3453-8. Abstract only.	
		ZHENG et al., DNA containing CpG motifs induces angiogenesis. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8944-9. Epub 2002 Jun 11.	
		ZOU et al., Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection. Eur J Immunol. 2001 Dec;31(12):3833-9. Abstract only.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for judgment based on failure to comply with 35 U.S.C. 135(b)). (Electronically filed, unsigned). June 7, 2004.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in fact). (Electronically filed, unsigned). June 7, 2004.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of enablement). (Electronically filed, unsigned). June 7, 2004.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 6 (for judgment based on lack of adequate written description). (Electronically filed, unsigned). June 7, 2004.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 7 (motion to redefine interference to designate claims as not corresponding to the Count). (Electronically filed, unsigned). June 7, 2004.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 8 (contingent motion to redefine the Count). (Electronically filed, unsigned). June 7, 2004.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 9 (motion for benefit of earlier application). (Electronically filed, unsigned). June 7, 2004.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.:	09/630,319	ATTY. DOCKET NO.:	C1039.70042US00
FILING DATE:	July 31, 2000	CONFIRMATION NO.:	5464
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

Sheet	17	of	19
-------	----	----	----

	Patent Interference No. 105,171. Iowa Preliminary Motion 10 (contingent motion to redefine the interference by adding a continuation application). (Electronically filed, unsigned). July 2, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa Preliminary Motion 6 for judgment based on lack of adequate written description). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa Preliminary Motion 7 to redefine the interference). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa Preliminary Motion 8 to redefine the Count). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa Contingent Motion 9 for benefit). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa Contingent Motion 10 to redefine the interference). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 11 (to Iowa Contingent Motion 11 to suppress). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment of no interference in fact) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for judgment based on lack of adequate written description) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine the count) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 11 (in support of Iowa Miscellaneous Motion to suppress). (Electronically filed, unsigned). October 18, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to designate additional claims of Iowa patent as corresponding to the Count). June 7, 2004.	

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/630,319		ATTY. DOCKET NO.: C1039.70042US00	
				FILING DATE: July 31, 2000		CONFIRMATION NO.: 5464	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	18	of	19				

		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for judgment based on lack of written description support and introducing new matter). June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (for judgment based on anticipation). June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (for judgment based on obviousness). June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (for judgment based on anticipation). June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (for judgment based on inequitable conduct). June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 7 (for benefit of an earlier application under 37 CFR 1.633(j)). July 2, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.	
		Amended Claims for Application Number 09/265,191, filed March 10, 1999.	
		Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633 (2) and (i)) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 1 (to Iowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
APPLICANT: Krieg et al.	
GROUP ART UNIT: 1648	EXAMINER: Emily M. Le

Sheet	19	of	19
-------	----	----	----

		Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.	
		Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005.	
		Patent Interference No. 105,171. Judgment and Order. March 10, 2005.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------


* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
APPLICANT: Krieg et al.	
GROUP ART UNIT: 1648	EXAMINER: Emily M. Le

**U.S. PATENT DOCUMENTS**

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,663,153		Hutcherson et al.	09-02-1997
		5,723,335		Hutcherson et al.	03-03-1998
		6,221,882	B1	Macfarlane	04-24-2001
		6,399,630	B1	Macfarlane	06-04-2002
		6,479,504	B1	Macfarlane et al.	11-12-2002
		6,521,637	B2	Macfarlane	02-18-2003
		6,552,006	B2	Raz et al.	04-22-2003
		6,589,940	B1	Raz et al.	07-08-2003
		6,727,230	B1	Hutcherson et al.	04-27-2004
		6,835,395	B1	Semple et al.	12-28-2004
		6,943,240	B2	Bauer et al.	09-13-2005
		6,949,520	B1	Hartmann et al.	09-27-2005
		7,001,890	B1	Wagner et al.	02-21-2006
		7,223,741	B2	Krieg	05-29-2007
		7,271,156	B2	Krieg et al.	07-18-2007
		2001-0044416	A1	McCluskie et al.	11-22-2001
		2002-0091097	A1	Bratzler et al.	07-11-2002
		2002-0156033	A1	Bratzler et al.	10-24-2002
		2002-0164341	A1	Davis et al.	11-07-2002
		2002-0165178	A1	Schetter et al	11-07-2002
		2002-0198165	A1	Bratzler et al.	12-26-2002
		2003-0026782	A1	Krieg	02-02-2003
		2003-0026801	A1	Weiner et al.	02-06-2003
		2003-0050263	A1	Krieg et al.	03-13-2003
		2003-0050268	A1	Krieg et al.	03-13-2003
		2003-0055014	A1	Bratzler	03-20-2003
		2003-0091599	A1	Davis et al.	05-15-2003
		2003-0100527	A1	Krieg et al.	05-29-2003
		2003-0139364	A1	Krieg et al.	07-24-2003
		2003-0148316	A1	Lipford et al.	08-07-2003
		2003-0148976	A1	Krieg et al.	08-07-2003
		2003-0166001	A1	Lipford	09-04-2003

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.:	09/630,319	ATTY. DOCKET NO.:	C1039.70042US00
FILING DATE:	July 31, 2000	CONFIRMATION NO.:	5464
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

Sheet	2	of	9	GROUP ART UNIT: 1648	EXAMINER: Emily M. Le
		2003-0181406	A1	Schetter et al.	09-25-2003
		2003-0191079	A1	Krieg et al.	10-09-2003
		2003-0212028	A1	Raz et al.	11-13-2003
		2003-0224010	A1	Davis et al.	12-04-2003
		2003-0232074	A1	Lipford et al.	12-18-2003
		2003-0232856	A1	Macfarlane	12-18-2003
		2004-0009949	A1	Krieg	01-15-2004
		2004-0030118	A1	Wagner et al.	02-12-2004
		2004-0053880	A1	Krieg	03-18-2004
		2004-0067902	A9	Bratzler et al.	04-08-2004
		2004-0067905	A1	Krieg	04-08-2004
		2004-0087534	A1	Krieg et al.	05-06-2004
		2004-0087538	A1	Krieg et al.	05-06-2004
		2004-0092472	A1	Krieg	05-13-2004
		2004-0106568	A1	Krieg et al.	06-03-2004
		2004-0131628	A1	Bratzler et al.	07-08-2004
		2004-0132685	A1	Krieg et al.	07-08-2004
		2004-0142469	A1	Krieg et al.	07-22-2004
		2004-0143112	A1	Krieg et al.	07-22-2004
		2004-0147468	A1	Krieg et al.	07-29-2004
		2004-0152649	A1	Krieg	08-05-2004
		2004-0152656	A1	Krieg et al.	08-05-2004
		2004-0198680	A1	Krieg	10-07-2004
		2005-0070491	A1	Krieg et al.	03-31-2005
		2005-0075302	A1	Hutcherson et al.	04-07-2005
		2005-0100983	A1	Bauer et al.	05-12-2005
		2005-0101554	A1	Krieg et al.	05-12-2005
		2005-0101557	A1	Krieg et al.	05-12-2005
		2005-0119273	A1	Lipford et al.	06-02-2005
		2005-0123523	A1	Krieg et al.	06-09-2005
		2005-0130911	A1	Uhlmann et al.	06-16-2005
		2005-0148537	A1	Krieg et al.	07-07-2005
		2005-0169888	A1	Hartman et al.	08-04-2005
		2005-0171047	A1	Krieg et al.	08-04-2005
		2005-0181422	A1	Bauer et al.	08-18-2005
		2005-0182017	A1	Krieg	08-18-2005

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/630,319		ATTY. DOCKET NO.: C1039.70042US00	
				FILING DATE: July 31, 2000		CONFIRMATION NO.: 5464	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	3	of	9				

		2005-0197314	A1	Krieg et al.	09-08-2005
		2005-0215501	A1	Lipford et al.	09-29-2005
		2005-0233995	A1	Krieg et al.	10-20-2005
		2005-0233999	A1	Krieg et al.	10-20-2005
		2005-0239732	A1	Krieg et al.	10-27-2005
		2005-0239733	A1	Jurk et al.	10-27-2005
		2005-0239734	A1	Uhlmann et al.	10-27-2005
		2005-0239736	A1	Krieg et al.	10-27-2005
		2005-0244379	A1	Krieg et al.	11-03-2005
		2005-0244380	A1	Krieg et al.	11-03-2005
		2005-0245477	A1	Krieg et al.	11-03-2005
		2005-0250726	A1	Krieg et al.	11-10-2005
		2005-0256073	A1	Lipford et al.	11-17-2005
		2005-0267064	A1	Krieg et al.	12-01-2005
		2005-0277604	A1	Krieg et al.	12-15-2005
		2005-0277609	A1	Krieg et al.	12-15-2005
		2006-0003955	A1	Krieg et al.	01-05-2006
		2006-0003962	A1	Ahluwalia et al.	01-05-2006
		2006-0019239	A1	Ivins et al.	01-26-2006
		2006-0019916	A1	Krieg et al.	01-26-2006
		2006-0019923	A1	Davis et al.	01-26-2006
		2006-0058251	A1	Krieg et al.	03-16-2006
		2006-0089326	A1	Krieg et al.	04-27-2006
		2006-0094683	A1	Krieg et al.	05-04-2006
		2006-0140875	A1	Krieg et al.	06-29-2006
		2006-0154890	A1	Bratzler et al.	07-13-2006
		2006-0172966	A1	Lipford et al.	08-03-2006
		2006-0188913	A1	Krieg et al.	08-24-2006
		2006-0211639	A1	Bratzler et al.	09-21-2006
		2006-0211644	A1	Krieg et al.	09-21-2006
		2006-0229271	A1	Krieg et al.	10-12-2006
		2006-0241076	A1	Uhlmann et al.	10-26-2006
		2006-0246035	A1	Ahluwalia et al.	11-02-2006
		2006-0286070	A1	Hartmann et al.	12-21-2006
		2006-0287263	A1	Davis et al.	12-21-2006
		2007-0009482	A1	Krieg et al.	01-11-2007

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.:	09/630,319	ATTY. DOCKET NO.:	C1039.70042US00
FILING DATE:	July 31, 2000	CONFIRMATION NO.:	5464
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

Sheet 4 of 9

	2007-0010470	A1	Krieg et al.	01-11-2007
	2007-0037767	A1	Bratzler et al.	02-15-2007
	2007-0065467	A1	Krieg et al.	03-22-2007
	2007-0066553	A1	Krieg et al.	03-22-2007
	2007-0066554	A1	Krieg et al.	03-22-2007
	2007-0078104	A1	Krieg et al.	04-05-2007
	2007-0129320	A9	Davis et al.	06-07-2007
	2007-0142315	A1	Forsbach et al.	06-21-2007
	2007-0184465	A1	Wagner et al.	08-09-2007
	2007-0202128	A1	Krieg et al.	08-30-2007
	2007-0224210	A1	Krieg et al.	09-27-2007
	2007-0232622	A1	Lipford et al.	10-04-2007

FOREIGN PATENT DOCUMENTS

Examiner's Initials ^a	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		EP	0 468 520	A2	Mitsui Toatsu Chemicals, Inc.	01-29-1992	
		WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999	
		WO	00/06588	A1	University of Iowa Research Foundation	02-10-2000	
		WO	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000	
		WO	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000	
		WO	2004/026888	A2	Coley Pharmaceutical GMBH	04-01-2004	
		WO	2004/094671	A2	Coley Pharmaceutical GMBH	11-04-2004	
		WO	2006/080946	A2	Coley Pharmaceutical GMBH	08-03-2006	
		WO	2007/031877	A2	Coley Pharmaceutical GMBH	03-22-2007	
		WO	2007/038720	A2	Coley Pharmaceutical GMBH	04-05-2007	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials ^a	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Press Release, January 2007, "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy".	
		Press Release, June 2007, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer".	
		ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced	

EXAMINER:

DATE CONSIDERED:

^a EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/630,319		ATTY. DOCKET NO.: C1039.70042US00	
				FILING DATE: July 31, 2000		CONFIRMATION NO.: 5464	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1648		EXAMINER: Emily M. Le	
Sheet	5	of	9				

		secretion of interleukin-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8.	
		BAFICA et al., TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med. 2005 Dec 19;202(12):1715-24.	
		BALLAS et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996 Sep 1;157(5):1840-5.	
		BRANDA et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem-Pharmacol. 1993 May 25;45(10):2037-43.	
		BRANDA et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J Lab Clin Med. 1996 Sep;128(3):329-38.	
		BRANDA et al., B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol. 1996 May;79(2):115-21.	
		CHU et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997 Nov 17;186(10):1623-31.	
		COWDERY et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol. 1996 Jun 15;156(12):4570-5.	
		ELKINS et al., Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol. 1999 Feb 15;162(4):2291-8.	
		FREIDAG et al., CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect Immun. 2000 May;68(5):2948-53.	
		HALPERN et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol. 1996 Jan 10;167(1):72-8.	
		HOGARTH et al., Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs. Vaccine. 2003 Feb 14;21(9-10):977-82.	
		HSIEH et al., Incorporation of CpG oligodeoxynucleotide fails to enhance the protective efficacy of a subunit vaccine against Mycobacterium tuberculosis. Vaccine. 2004 Jan 26;22(5-6):655-9.	
		ITO et al., CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans. Infect Immun. 2005 Sep;73(9):6154-6.	
		JUFFERMANS et al., CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect Immun. 2002 Jan;70(1):147-52.	
		KATAOKA et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG. Jpn J Cancer Res. 1992 Mar;83(3):244-7.	
		KIMURA et al., Binding of oligodeoxynucleotide to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. J Biochem (Tokyo). 1994 Nov;116(5):991-4.	
		KLINMAN et al., Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun. 1999 Nov;67(11):5658-63.	
		KLINMAN et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83.	
		KRIEG et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 1996 Summer;6(2):133-9.	

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.:	09/630,319	ATTY. DOCKET NO.:	C1039.70042US00
FILING DATE:	July 31, 2000	CONFIRMATION NO.:	5464
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1648	EXAMINER:	Emily M. Le

Sheet 6 of 9

	KRIEG et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev. 1995 Winter;5(4):241.	
	KRIEG, CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol. 1995 Nov;15(6):284-92.	
	KRIEG et al., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546-9.	
	KRIEG, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med. 1996 Aug;128(2):128-33.	
	KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.	
	KRIEG et al., Infection. In: McGraw Hill Book. 1996:242-3.	
	KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec;27(6):460-71.	
	KRIEG, Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84.	
	KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8.	
	KURAMOTO et al., Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res. 1992 Nov;83(11):1128-31.	
	MESSINA et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Cell Immunol. 1993 Mar;147(1):148-57.	
	OXENIUS et al., CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol. 1999 May;73(5):4120-6.	
	PISETSKY et al., The immunologic properties of DNA. J Immunol. 1996 Jan 15;156(2):421-3.	
	PISETSKY et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 1994;54(2):101-7.	
	PISETSKY, Immunologic consequences of nucleic acid therapy. Antisense Res Dev. 1995 Fall;5(3):219-25.	
	PISETSKY et al., Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. Mol Biol Rep. 1993 Oct;18(3):217-21.	
	RYNKIEWICZ et al., Marked enhancement of antibody response to anthrax vaccine adsorbed with CPG 7909 in healthy volunteers. 45 th Intersci. Conf. Antimicrob. Agents Chemother. 2005 Sep. 21-24; New Orleans, Louisiana. Meeting Poster.	
	SATO et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 1996 Jul 19;273(5273):352-4.	
	SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J Interferon Cytokine Res. 1996 Oct;16(10):799-803.	
	STACEY et al. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun. 1999 Aug;67(8):3719-26.	

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1648	EXAMINER: Emily M. Le
Sheet	7	of	9		

		STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. <i>Antisense Res Dev.</i> 1994 Summer;4(2):67-9.	
		STEIN et al., Non-antisense effects of oligodeoxynucleotides. <i>Antisense Technology.</i> 1997; ch11: 241-64.	
		TOKUNAGA et al., A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. <i>Jpn J Cancer Res.</i> 1988 Jun;79(6):682-6.	
		TOKUNAGA et al., Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells. <i>Microbiol Immunol.</i> 1992;36(1):55-66.	
		WANG et al., CpG oligonucleotides partially inhibit growth of <i>Mycobacterium tuberculosis</i> , but not <i>Salmonella</i> or <i>Listeria</i> , in human monocyte-derived macrophages. <i>FEMS Immunol Med Microbiol.</i> 2005 Aug 1;45(2):303-10.	
		WEDLOCK et al., Vaccination of cattle with <i>Mycobacterium bovis</i> culture filtrate proteins and CpG oligodeoxynucleotides induces protection against bovine tuberculosis. <i>Vet Immunol Immunopathol.</i> 2005 Jun 15;106(1-2):53-63.	
		YAMAMOTO et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. <i>Microbiol Immunol.</i> 1994;38(10):831-6.	
		YAMAMOTO et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. <i>J Immunol.</i> 1992 Jun 15;148(12):4072-6.	
		YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from <i>Mycobacterium bovis</i> BCG] <i>Kekkaku.</i> 1994 Sep;69(9):571-4. Japanese.	
		YAMAMOTO et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. <i>Antisense Res Dev.</i> 1994 Summer;4(2):119-22.	
		YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. <i>Jpn J Cancer Res.</i> 1994 Aug;85(8):775-9.	
		YI et al., Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. <i>J Immunol.</i> 1996 Dec 15;157(12):5394-402.	
		YI et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. <i>J Immunol.</i> 1996 Jan 15;156(2):558-64.	
		ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):495-502.	
		Patent Interference No. 105,171. Regents of the University of California. Brief of Appellant. July 5, 2005.	
		Patent Interference No. 105,171. University of Iowa and Coley Pharmaceutical Group, Inc. Brief of Appellees. August 17, 2005.	
		Patent Interference No. 105,171. Regents of the University of California. Reply Brief of Appellant.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered.
Include copy of this form with next submission to the examiner.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1648	EXAMINER: Emily M. Le
Sheet	8	of	9		

		September 6, 2005.	
		Patent Interference No. 105,171. Regents of the University of California. Decision of CAFC. July 17, 2006.	
		Patent Interference No. 105,526. Krieg Substantive Motion 1 (for unpatentability based on interference estoppel). (Electronically filed, unsigned).	
		Patent Interference No. 105,526.. Krieg Substantive Motion 2 (for judgment based on inadequate written description and/or enablement). (Electronically filed, unsigned). June 18, 2007.	
		Patent Interference No. 105,526. Krieg Contingent Responsive Motion (to add new claims 104 and 105). (Electronically filed, unsigned). July 25, 2007.	
		Patent Interference No. 105,526. Krieg Substantive Motion 3 (for judgment based on prior art). (Electronically filed, unsigned). June 18, 2007.	
		Patent Interference No. 105,526. Raz Motion 1 (Unpatentability of Krieg Claims under 35 U.S.C. § 112, First Paragraph). (Electronically filed, unsigned). June 18, 2007.	
		Patent Interference No. 105,526. Raz Motion 2 (Raising a Threshold Issue of No Interference-in-Fact). (Electronically filed, unsigned). June 18, 2007.	
		Patent Interference No. 105,526. Raz Motion 3 (Krieg's Claims are Unpatentable Over Prior Art Under 35 U.S.C. § 102(b)) (Electronically filed, unsigned). June 18, 2007.	
		Patent Interference No. 105,526. Raz Motion 4 (To Designate Krieg Claims 46 and 82-84 as Corresponding to Count 1). (Electronically filed, unsigned). June 18, 2007.	
		Patent Interference No. 105,526. Raz Responsive Miscellaneous Motion 5 (To revive the Raz Parent Application) (Electronically filed, unsigned) July 25, 2007.	
		Patent Interference No. 105,526. Raz Contingent Responsive Motion 6 (To Add a New Claim 58) (Electronically filed, unsigned) July 25, 2007.	
		Patent Interference No. 105,526. Krieg Opposition 1 (Opposition to Motion for Lack of Enablement and Written Description) (Electronically filed, unsigned) September 10, 2007.	
		Patent Interference No. 105,526. Krieg Opposition 2 (to Raz Motion 2) (Electronically filed, unsigned) September 10, 2007.	
		Patent Interference No. 105,526. Krieg Opposition 3 (To Raz Motion 3) (Electronically filed, unsigned) September 10, 2007.	
		Patent Interference No. 105,526. Krieg Opposition 4 (Opposition to Motion for Designating Claims 46 and 82-84 as Corresponding to the Court) (Electronically filed, unsigned) September 10, 2007.	
		Patent Interference No. 105,526. Krieg Opposition 6 (Opposition to Raz Contingent Responsive Motion 6) (Electronically filed, unsigned) September 10, 2007.	
		Patent Interference No. 105,526. Raz Opposition 1 (Opposing Krieg Substantive Motion 1) (Electronically filed, unsigned) September 10, 2007.	
		Patent Interference No. 105,526. Raz Opposition 2 (Opposing Krieg Substantive Motion 2) (Electronically filed, unsigned) September 10, 2007.	
		Patent Interference No. 105,526. Raz Opposition 4 (Opposing Krieg Contingent Responsive Motion to Add New Claims 104 and 105) (Electronically filed, unsigned) September 10, 2007.	
		Patent Interference No. 105,526. Krieg Reply 1 (Reply to Raz opposition 1) October 5, 2007	
		Patent Interference No. 105,526. Krieg Reply 2 (Reply to Raz opposition 2) October 5, 2007	
		Patent Interference No. 105,526. Krieg Reply 4 (Reply to Raz opposition 4) October 5, 2007	
		Patent Interference No. 105,526. Raz Reply 1 (Reply to Krieg opposition 1) October 5, 2007	

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1648	EXAMINER: Emily M. Le
Sheet	9	of	9		

	Patent Interference No. 105,526. Raz Reply 2 (Reply to Krieg opposition 2) October 5, 2007	
	Patent Interference No. 105,526. Raz Reply 3 (Reply to Krieg opposition 3) October 5, 2007	
	Patent Interference No. 105,526. Raz Reply 4 (Reply to Krieg opposition 4) October 5, 2007	
	Patent Interference No. 105,526. Raz Reply 6 (Reply to Krieg opposition 6) October 5, 2007	
	Patent Interference No. 105,526. Krieg Miscellaneous Motion 5 (To exclude exhibits 2066, 2070, 2071, 2072, 2073, 2074, 2075, 2076 and 2078) October 9, 2007.	
	Patent Interference No. 105,526. Raz Opposition 5 (Opposing Krieg Miscellaneous Motion 5) October 25, 2007.	
	Patent Interference No. 105,526. Raz Miscellaneous Motion 7 (To exclude evidence) October 19, 2007.	
	Patent Interference No. 105,526. Krieg Opposition 7 (To Raz Miscellaneous Motion 7) October 25, 2007.	
	Patent Interference No. 105,526. Krieg Reply 5 (Reply to Raz opposition 5) October 30, 2007.	
	Patent Interference No. 105,526. Raz Reply 7 (Reply to Krieg opposition 7) October 30, 2007.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications)

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /Emily Le/	DATE CONSIDERED: 03/15/2008
-----------------------------	------------------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./